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Abstract
Background—Shared decision-making (SDM) is a widely recommended yet unproven strategy
for increasing colorectal cancer (CRC) screening uptake. Previous trials of decision aids to
increase SDM and CRC screening uptake have yielded mixed results.
Purpose—To assess the impact of decision aid–assisted SDM on CRC screening uptake.
Design—RCT.
Setting/participants—The study was conducted at an urban, academic safety-net hospital and
community health center between 2005 and 2010. Participants were asymptomatic, average-risk
patients aged 50–75 years due for CRC screening.
Intervention—Study participants (n=825) were randomized to one of two intervention arms
(decision aid plus personalized risk assessment or decision aid alone) or control arm. The
interventions took place just prior to a routine office visit with their primary care providers.
Main outcome measures—The primary outcome was completion of a CRC screening test
within 12 months of the study visit. Logistic regression was used to identify predictors of test
completion and mediators of the intervention effect. Analysis was completed in 2011.
Results—Patients in the decision-aid group were more likely to complete a screening test than
control patients (43.1% vs 34.8%; p=0.046) within 12 months of the study visit; conversely, test
uptake for the decision aid and decision aid plus personalized risk assessment arms was similar
(43.1% vs 37.1%; p=0.15). Assignment to the decision-aid arm (AOR 1.48; 95% CI=1.04, 2.10),
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black race (AOR 1.52, 95% CI=1.12, 2.06) and a preference for a patient-dominant
decisionmaking approach (AOR, 1.55; 95% CI=1.02, 2.35) were independent determinants of test
completion. Activation of the screening discussion and enhanced screening intentions mediated
the intervention effect.
Conclusions—Decision aid–assisted SDM has a modest impact on CRC screening uptake. A
decision aid plus personalized risk assessment tool is no more effective than a decision aid alone.
Introduction
Colorectal cancer remains a leading cause of cancer-related morbidity and mortality, despite
recent declines in both incidence and mortality.1,2 A compelling body of evidence has
accumulated to suggest that screening is the most effective and rational strategy for further
reducing the public health burden of this deadly yet potentially preventable disease.
Consequently, screening is now endorsed by most, if not all, authoritative groups, including
the U.S. Preventive Services Task Force, American Cancer Society, and U.S. Multi-society
Task Force on Colorectal Cancer.3,4 These endorsements, combined with more-widespread
coverage by medical insurers and heightened public awareness efforts, have contributed to a
steady increase in screening prevalence in recent years. Nevertheless, more than one third of
age-eligible Americans have never been screened.5
Eliciting patient preference within the context of shared decision-making (SDM) has been
advocated as a potentially effective strategy for increasing patient acceptance and adherence
to CRC screening recommendations.3,4 Engaging patients to participate in the decision-
making process when confronted with preference-sensitive choices related to CRC screening
is also fundamental to the concept of patient-centered care.6–8 CRC screening is ideally
suited for this approach given the availability of multiple options with distinct advantages
and disadvantages, the lack of consensus regarding an optimal cost-effective strategy, and
limited effectiveness of the more-traditional paternalistic approach in which providers
assume full responsibility for the decision-making process. Further support is derived from
studies finding that both patients and providers hold distinct preferences for the various
screening options,9–14 that providers often misperceive patient preferences,10 and that many
patients endorse an SDM approach for CRC screening.15,16
Despite a compelling rationale, SDM has been difficult to implement in routine clinical
practice in part due to lack of time, resources, clinician expertise and suitability for certain
patients or clinical situations.17,18 The use of patient-oriented decision aids has been
proposed as a potentially effective strategy for circumventing several of these barriers.8,19
Decision aids help patients make informed, value-concordant choices about a particular
course of action based on an understanding of potential benefits, risks, probabilities and
scientific uncertainty.20 Studies to date have shown that decision aids for CRC screening
enable users to identify a preferred screening option,11,16,21–25 reduce decisional
conflict22,24 and increase interest in screening.21,23,25,26 The authors have recently shown
that decision aids can also facilitate SDM by increasing patient knowledge, increasing
satisfaction with the decision-making process, enhancing screening intentions, and
improving the quality and efficiency of the patient–provider encounter.16,27
The extent to which decision aids increase CRC screening uptake, however, is less well-
defined.21–25,28 Hence, the primary objective of this study was to test the hypothesis that
decision-aid users were more likely to complete a CRC screening test than non-users. Unlike
previous such studies, effectiveness was evaluated within the context of a shared rather than
informed decision-making framework.29 Based on evidence suggesting that individualized
risk communication might also increase uptake of screening tests,30 a secondary objective
was to test the hypothesis that a modified version of the decision aid which incorporated a
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validated personalized risk assessment tool for CRC would be more effective than the
decision aid alone for increasing test completion. .
Methods
Study Population and Recruitment Process
The study sample was made up of average-risk primary care patients cared for at Boston
Medical Center or the South Boston Community Health Center. Patients were deemed
eligible if they were aged 50–75 years and due for CRC screening.3,4 Patients meeting any
of the following criteria were excluded: (1) prior CRC screening by any method other than
fecal occult blood testing (FOBT); (2) high-risk condition (personal history of colorectal
cancer or polyps, family history of colorectal cancer or polyps involving one or more first-
degree relatives, or chronic inflammatory bowel disease); (3) lack of fluency in written and
spoken English; or (4) comorbidities that preclude CRC screening by any recommended
method, as determined by primary care provider (PCP). The decision to exclude patients
with prior screening other than FOBT was based on concerns that such patients may be more
likely to adhere to repeat testing than previously unscreened patients. Conversely, patients
with prior FOBT were included because of institutional data suggesting that they were less
likely to adhere to repeat testing and thus potentially more likely to consider alternative
screening options after reviewing the decision aid.
Three different recruitment strategies were used during the course of the study. The vast
majority of patients (n=796) were recruited using an “opt-out” approach in which patients
due for screening were identified from monthly audits of the electronic medical record 2–4
weeks prior to a scheduled office visit and contacted directly by telephone by a research
assistant if deemed appropriate by the patient’s PCP. Those expressing interest were
provided with a brief overview of the study, evaluated for eligibility and invited to
participate. Two other PCP-mediated strategies, including an “opt-in” electronic flagging
approach (n=12) and “opt-in” letter approach (n=17), were used initially but were
discontinued after 6 months due to low enrollment. Details of each of these approaches and
their relative cost effectiveness have been previously published.31
Setting
The study was conducted at two urban ambulatory care sites. The first, Boston Medical
Center (BMC), is an urban, nonprofit academic medical center affiliated with the Boston
University School of Medicine, which serves a mostly low-income, racially/ethnically-
diverse patient population. The second, the South Boston Community Health Center
(SBCHC), is a community health center affiliated with BMC, which serves a mostly non-
Hispanic white, low-income patient population. Both sites use the same electronic medical
record system (Centricity™ ). The study protocols were approved for both sites by the
Boston University Medical Campus IRB.
Provider Characteristics and Training
Sixty-one primary care providers, including 47 board-certified general internists, 11 board-
certified family physicians and three nurse practitioners, practicing at both BMC and the
SBCHC participated in the study. Pre-trial training seminars and annual refreshers were
conducted at both sites to educate providers about the current status of CRC screening
highlighting the recommendation for SDM, provide an overview of the study design, and
elicit support. The meetings also provided a venue for informing participating providers
about the status of recruitment and addressing any logistic problems that they experienced
related to the study. All providers attended at least one of the meetings. By design, no formal
training in SDM was undertaken.
Schroy et al. Page 3














An RCT was conducted between April 2005 and December 2010 to evaluate the impact of
the decision aid on SDM and screening behavior. Eligible patients were instructed to arrive
1 hour before a prearranged chronic care visit with their primary care provider. Each
received a pre-visit reminder call to ensure that the patient had no acute medical illnesses
that would preclude the CRC screening discussion.
After informed consent was obtained, patients were administered a 10-minute, paper-based
pretest that assessed knowledge, beliefs, attitudes and behaviors related to CRC screening,
as well as level of desire for participating in decision-making related to CRC screening. The
pretest was administered using a structured interviewer format by one of four trained
research assistants in a private office located in one of the ambulatory care clinics of the
participating sites. After completing the pretest, patients were randomized to one of two
intervention arms (decision aid alone or decision aid plus YourDiseaseRisk (YDR;
personalized risk assessment tool with feedback) or usual care with stratification by
provider. Patients randomized to the usual care arm reviewed a modified online version of
“9 Ways to Stay Healthy and Prevent Disease”, which discussed generic lifestyle changes
other than screening for minimizing risk of preventable diseases.
Immediately after completing the interactive computer session, patients met with their
providers to discuss screening and identify a preferred screening strategy. Providers received
written notification hand-delivered by all the patients acknowledging that they were
participating in the “CRC decision aid study” at the time of the visit to ensure that screening
was discussed; no information was provided regarding preferences or factors influencing
choice for patients in the intervention arms. Before leaving the clinic, patients completed a
10-minute, paper-based post-test, again using a structured interviewer format, which
assessed whether CRC screening was discussed, whether a screening strategy was chosen,
patient satisfaction with the decisionmaking process, and screening intentions; the post-test
also reassessed knowledge, beliefs, and attitudes related to CRC screening.
Decision Aid
Details of the decision-aid’s theoretic framework, development, content and usability testing
have been previously published16 In brief, the DVD-formatted tool employed an audiovisual
and touch-screen design to simplify use for individuals with limited literacy and/or computer
skills. The tool consists of a series of modules, in which professional actors playing the role
of a black, Hispanic female moderator and a white, non-Hispanic male physician convey
relevant information via on-screen video, animation and/or graphics.
The modules include: (1) an introductory segment that briefly discusse the importance of
screening, purpose of the tool and instructions in its use; (2) a brief overview of the
epidemiology of CRC, natural history, benefits of screening, availability of multiple
screening options, and the lack of consensus regarding a best screening method; (3) brief
descriptions of five screening methods (FOBT, flexible sigmoidoscopy, the combination of
FOBT plus flexible sigmoidoscopy, DCBE and colonoscopy) endorsed at the time the study
was initiated32–34; (4) audio and visual comparisons of each method with respect to
individual test features; (5) a summary of the different test features for each method with
optional links to additional information about the preparation or test itself, as well as
vignettes from patients describing their experience with a particular test; and (6) a decision-
making module where users are asked to identify a screening preference (including no
screening) and rank-order test features influencing their selection; and (7) a concluding
segment in which the narrator encourages the user to discuss screening and their preferences
with their doctor.
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A modified version of the decision aid was also created that incorporated the web-based
YDR CRC risk assessment tool (www.yourdiseaserisk.wustl.edu), in order to assess whether
personalized 10-year CRC risk feedback influenced decision-making. The risk estimate was
conveyed using qualitative framing (“very much below average risk” to “very much above
average risk”) with accompanying suggestions for behavior modifications that might reduce
risk, including a strong recommendation for screening, regardless of risk. The decision aid
took between 20 and 30 minutes to complete, depending on which of the optional segments
users chose to review.
Measures
The primary outcome measure was completion of a CRC screening test within 12 months of
the study visit. Because of long waiting times (≥3 months) and high cancellation rates
(>20%) at the start of the study, the 12-month time frame was selected a priori to allow
sufficient time for patients who needed to cancel an endoscopic screening procedure to
complete the rescheduled examination. Secondary outcomes included test uptake at 6
months and test ordering at 1, 3, 6 and 12 months post-study visit.
All outcomes were tracked using electronic clinical data reporting systems, which captured
results for all endoscopic procedures, imaging studies and FOBT completed at the
participating sites, and evaluated using an intention-to-treat analysis. Other outcomes of
interest included the identification of predictors of test completion and mediators of the
intervention effect. Mediators were defined as measures that: (1) significantly changed as a
consequence of the intervention (e.g., screening intentions16); (2) had a significant
independent effect on the primary outcome of interest (i.e., test completion); and (3)
diminished the intervention’s effect on the primary outcome in the adjusted model.35
Sample Size and Power Considerations
Sample size and power considerations focused on a two-group comparison of the decision
aid alone versus control study arms for the primary outcome of CRC screening test
completion at 12 months. Based on crude estimates of baseline test uptake, it was
determined that a target sample of 275 subjects per arm provided greater than 80% power of
detecting a 54% versus 40% difference in the percentage of patients completing a CRC
screening test within 12 months of the study visit.
Statistical Analyses
Data analysis was completed in 2011. As a check on randomization, the three study groups
were first compared on demographic characteristics, prior FOBT screening, risk perception
and desired role in decision-making through the chi-square test of independence. Chi-square
tests were also used to compare the percentage of patients in the decision aid –alone group
to those in the control group or decision aid plus YDR group who either had a test ordered
or completed at each of the designated time points. Logistic regression was used to identify
patient-level determinants of test completion and mediators of the intervention effect.
Details regarding measurement of patient knowledge, satisfaction with the decision-making
process and screening intentions were previously published.16 Variables exhibiting a
significant association with test completion in univariate analyses at the two-tailed p<0.05
level were included as covariates in the multivariate analyses. Sobel tests were performed to
assess significance for the mediation analyses.36 All other analyses were conducted using
SAS 9.2.
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Of the 13,518 patients identified as potentially eligible for screening because of age, 7619
(56%) were deemed ineligible (mostly due to prior screening [n=6073]) and 5074 (38%)
were excluded (Figure 1). Reasons for exclusion included: inability to contact (n=4321);
disinterest (n=290); scheduling conflict (n=305); and failure to keep appointment (n=158).
The remaining 825 patients (52% of eligible subjects contacted) were enrolled and
randomized to decision aid–alone (n=269); decision aid plus YDR (n=280); or control (n=
76) arms.
The three study arms were well-balanced with respect to all baseline characteristics,
including patient age, gender, ethnicity, race, marital status, education, insurance coverage,
prior FOBT, and decision-making preference (Table 1). Overall, the study group was mostly
aged <65 years (84%); female (59%); non-Hispanic (95%); and black (62%), with at least a
high-school degree (78%). Only 36% were married or living with a partner. Although most
had some form of healthcare insurance (98%), nearly two thirds were covered by Medicare,
Medicaid or Massachusetts’ “Free Care” (now “Commonwealth Care”) program. Most
(87%) had no prior FOBT. The majority preferred a patient-dominant (27%) or shared-
decision-making approach (53%) for selecting a preferred CRC screening option.
Intervention Effects on Test Ordering and Completion
Patients in the decision aid–alone group were more likely to have a test ordered than the
control group at the 1-month (69.1% vs 60.5%, p<0.035); 3-month (71.8% vs 62.3%,
p=0.019); 6- month (77.0% vs 65.2%, p=0.002); and 12-month (80.7% vs 71.4%, p=0.011)
time points (Table 2). The decision aid–alone group was also more likely to have a test
ordered than the decision aid plus YDR group at each of these points, but here the
differences were only significant at 1 month (69.1% vs 60.4%; p<0.031); 6 months (77.0%
vs 67.1%, p<0.010); and 12 months (80.7% vs 73.6%, p=0.048). The pattern of test ordering
was similar for the three groups; regardless of patient preferences, colonoscopy was the
most commonly ordered test (range, 79%–81%) followed by FOBT (13%–19%); flexible
sigmoidoscopy (<2%); and barium enema (<2%).
Among the 525 intervention patients expressing a preference, 322 (61%) had their preferred
test ordered, 91 (17%) had an alternate test ordered, and 112 (21%) had no test ordered
(Table 3). For individual tests, concordance between patient preference and test ordered
varied from 81% for colonoscopy to 35% for FOBT, 28% for barium enema, 19% for
flexible sigmoidoscopy and 19% for FOBT plus flexible sigmoidoscopy. Patients who
preferred tests other than colonoscopy were less likely to have any test ordered than those
who preferred colonoscopy (69% vs 85%, p<0.001).
Test completion, the primary outcome of interest, was higher for the decision aid–alone
group than usual-care group at both the 6-month (34.2% vs 26.4%; p=0.049) and 12-month
(43.1% vs 34.8%; p=0.046) time points (Table 2). Test completion for the decision aid–
alone group and decision aid plus YDR group was similar at both time points (34.2% vs
30.0% at 6 months, p=0.292; 43.1% vs 37.1% at 12 months, p=0.153). Among the group of
intervention patients who had a test ordered, 12-month uptake was similar when there was
concordance or discordance between patient preference and test ordered (51% vs 58%;
p=0.199; Table 3).
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Associations Between Pre-Intervention Patient Characteristics and Test Completion
Table 4 depicts associations between baseline patient characteristics and test completion at
12 months. Assignment to the decision aid–alone study group (AOR 1.48, 95% CI=1.04,
2.10); black race (AOR 1.52, 95% CI=1.12, 2.06); and a preference for a patient-dominant
decision-making approach (AOR 1.55; 95% CI=1.02, 2.35) were independent predictors of
test completion. No associations were observed for site, age, gender, ethnicity, education,
marital status, insurance status, or prior FOBT. Similar results were observed for test
completion at 6 months (Appendix A, available online at www.ajpmonline.org), except that
black race was no longer significant in the adjusted analyses (AOR 1.18, 95% CI=0.86,
1.63).
Mediators of Intervention Effects
Patients in the decision aid-alone group were more likely than controls to discuss screening
at the study visit (93% vs 86%, p=0.008) even though all patients were given written
prompts to hand to their providers acknowledging their participation in the study. As
previously reported,16 other measures of SDM including post-test knowledge, satisfaction
with the decisionmaking process, and screening intention scores were also higher for the two
intervention groups than they were for controls (Appendix B, available online at
www.ajpmonline.org). Measures (Table 5) included: whether or not screening was discussed
at the study visit (AOR 3.24, 95% CI=1.73, 6.05) and whether screening intentions (AOR
1.69, 95% CI=1.25, 2.28) were independent post-intervention determinants of test
completion after adjustment for study group, race, and decision-making preference.
Controlling for both determinants diminished the positive association for the decision aid–
alone group (AOR, 1.30, 95% CI=0.90, 1.87), suggesting a mediation effect, which was
confirmed using Sobel tests for significance (screening discussion, p=0.026; intentions,
p=0.038). Post-intervention knowledge, satisfaction with the decisionmaking process,
patient preferences and concordance between patient preference and test ordered showed no
association with test completion.
Discussion
This study provides new evidence that decision aid–assisted SDM is an effective strategy for
increasing CRC screening. Test completion uptake was ∼8% higher among decision-aid
users than controls at both 6 and 12 months, suggesting a very modest but sustained impact
on screening uptake. Unlike previous such studies, this study also explored the role of
individual elements of SDM on screening behavior and found that the positive impact was
mediated through activation of the screening discussion and heightened screening intentions
rather than increased knowledge, satisfaction with the decision-making process, or
concordance between patient preference and test ordered. Because providers received
written notification of participation in the study from all patients, the authors speculate that
enhanced activation of the screening discussion in the decision-aid group was the result of
patient empowerment rather than differential provider behavior in response to the cue.
Additional findings were that use of a decision aid that incorporates a personalized risk
assessment tool fails to increase test completion compared to a decision aid lacking the tool.
Unlike for conditions where the benefits of screening are less certain, the primary goal of
SDM for CRC screening is to enable patients to identify a preferred screening option rather
than to decide whether or not to undergo screening.4,7,8 Consequently, personalized risk
feedback might have a detrimental effect without appropriate framing. Individuals deemed
to be at higher risk may be fearful of the potential findings, whereas those at lower risk may
feel that screening is unnecessary, especially if they overestimated their lifetime risk of
cancer before receiving the feedback.37
Schroy et al. Page 7













Results of the current study contribute to a growing body of evidence suggesting that
patient-level interventions alone have a relatively modest impact on CRC screening. The use
of tailored educational approaches,38–41 patient reminders,42,43 activation strategies44 and,
as previously noted, decisions aids,21–25, 28 have demonstrated either no effect or a slight
increases in screening uptake that rarely exceed 20% compared to control groups. With the
steady rise in screening prevalence nationally,5 this limited effectiveness could partly reflect
the challenges of trying to reach a more recalcitrant patient population. Regardless, this
experience highlights the need for additional multilevel interventions that address not only
patient- but also provider- and system-level barriers to participation.
Several clinical implications of the current study are notable. The findings and feedback
from providers attest to the feasibility and validity of using decision aids as a point-of-
contact intervention in clinical practice.27 The observation that patients who preferred a
patient-dominant decision-making style were more likely to complete screening provides
new evidence supporting the importance of assessing a patient’s desire to participate in the
decision-making process prior to engaging in SDM.
Conversely, the lack of association between concordance and test completion suggests that
complying with patient preferences may be less important in select patients than the
provider’s ability to effectively communicate his/her reasoning for recommending a
preferred strategy. However, failure to comply with patient preferences negatively
influenced test ordering and thus compromised the overall impact of SDM on screening
uptake. The observation that blacks were more likely than whites to complete a screening
test in a safety-net healthcare system corroborates previously published data suggesting that
barriers to access and socioeconomic inequalities rather than cognitive factors may be
largely responsible for racial disparities in screening rates.45
Limitations and Strengths
Limitations to this study include the fact that lack of provider blinding may have negatively
influenced the magnitude of the interventions’ effect on outcomes of interest. Second, no
attempt was made to assess the quality of the patient–provider discussion. Even though
satisfaction with the decision-making process was universally high (albeit higher in the
intervention groups), recent data suggest that most patient–provider discussions related to
CRC screening often fail to incorporate key elements of informed decision-making.15,46
Third, this study did not explore reasons for the large discrepancy between test ordering and
test completion for each of the study arms. Although outcome assessment does not preclude
the remote possibility that some patients may have completed tests elsewhere, the authors
speculate that well-described patient- and system-level barriers to participation are largely
responsible.47 Lastly, no attempt was made to assess the cost effectiveness of the
intervention from the perspective of the provider or healthcare center.
Despite these limitations, this study has several notable strengths. First, it is the largest study
to date to demonstrate that the use of decision aids to promote SDM has a positive impact on
screening behavior. Second, the use of an RCT study design, large sample size, and diverse
study population enhances both the internal and external validity of its findings. Third, the
randomization scheme after stratification by provider, and inclusion of mostly unscreened
patients, minimizes potential confounding.
Conclusion
This study finds that decision aid–assisted SDM has a modest impact on CRC screening
uptake, even when provider and patient preferences differ. The findings also suggest that
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decision aids not only enable patients to identify a value-concordant screening preference
but also empower them to initiate the screening discussion and heighten screening
intentions. Conversely, incorporating personalized risk feedback may have negative
consequences on screening behavior in the absence of appropriate messaging that motivates
patients to undergo screening regardless of risk. Despite its importance, however, SDM
alone is unlikely to have a profound impact on CRC screening uptake unless strategies are in
place to address patient- and system-level barriers to participation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Study flow diagram
PCP, primary care provider; YDR, YourDiseaseRisk personalized risk assessment tool with
feedback
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Table 1












  < 65 232 (83) 234 (87) 230 (83)
  ≥ 65 48 (17) 35 (13) 46 (17)
Gender 0.70
  Female 163 (58) 164 (61) 159 (58)
  Male 117 (42) 105 (39) 117 (42)
Ethnicity 0.35
  Non-Hispanic 262 (94) 259 (96) 261 (95)
  Hispanic 18 (6) 10 (4) 15 (5)
Race 0.52
  Black 172 (61) 160 (59) 180 (65)
  White 99 (35) 96 (36) 88 (32)
  Asian 3 (1) 7 (3) 2 (1)
  Other 6 (2) 6 (2) 6 (2)
Educationb 0.12
  ≥ High school 221 (79) 213 (80) 200 (74)
  < High school 58 (21) 52 (20) 72 (26)
Marital Status b 0.40
  Married 89 (32) 72 (27) 85 (31)
  Living with a partner 12 (4) 20 (7) 14 (5)
  Other 176 (64) 175 (66) 174 (64)
Insurance 0.06
  Private/HMO 85 (33) 95 (39) 76 (30)
  Medicare 79 (31) 58 (24) 86 (34)
  Medicaid 70 (28) 76 (31) 63 (25)
  Free care 14 (6) 11 (5) 16 (6)
  None 6 (2) 2 (1) 10 (4)
Prior FOBT b 0.90
  Yes 33 (12) 35 (13) 36 (13)
  No 243 (88) 232 (87) 239 (87)
Desired role in decision-making 0.54
  Mostly patient 75 (27) 66 (25) 81 (29)
  Shared 151 (54) 149 (55) 134 (49)
























  Mostly doctor 54 (19) 54 (20) 61 (22)
a
Chi-square test of independence
b
Missing data: education, n=9; marital status, n=8; prior FOBT, n=7.
YDR, YourDiseaseRisk personalized risk assessment tool with feedback; FOBT, fecal occult blood testing.
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Table 4









  Decision aid only 269 116 (43) 1.42 (1.01 , 2.01) 1.48 (1.04, 2.10)
  Decision aid + YDR 280 104 (37) 1.11 (0.78 , 1.57) 1.13 (0.80, 1.61)
  Control 276 96 (35) --- ---
Site
  BMC 763 297 (39) ---
  SBCHC 62 19 (31) 0.69 (0.40 , 1.21)
Age, years
  < 65 696 268 (39) ---
  ≥ 65 129 48 (37) 0.95 (0.64 , 1.40)
Gender
  Female 486 188 (39) 1.04 (0.78 , 1.38)
  Male 339 128 (38) --
Race
  White 283 92 (33) --- ---
  Black 512 214 (42) 1.49 (1.10 , 2.02) 1.52 (1.12, 2.06)
  Asian/Other 30 10 (33) 1.04 (0.47 , 2.31) 1.00 (0.45, 2.23)
Ethnicity
  Hispanic 43 16 (37) 0.95 (0.50 , 1.80)
  Non-Hispanic 782 300 (38) ---
Education
  < high school graduate
≥High school graduate
182 65 (36) ---
634 247 (39) 1.15 (0.82 , 1.62)
Marital Status
  Married/Living with partner
Unmarried/Living alone
246 100 (41) 1.15 (0.85 , 1.56)
571 213 (37) ---
Insurance, n(%)
  Private/HMO 256 111 (43) ---
  Medicare 223 81 (36) 0.74 (0.52, 1.08)
  Medicaid 209 78 (37) 0.78 (0.54, 1.13)
  Free care 41 18 (44) 1.02 (0.53, 1.99)
  None 18 8 (44) 1.04 (0.40, 2.74)
Prior FOBT
  Yes 104 40 (38) 1.01 (0.66, 1.54)





















  No 714 273 (38) ---
Decision-making
preference 222 97 (44) 1.52 (1.01 , 2.31) 1.55 (1.02, 2.35)
  Patient 434 162 (37) 1.17 (0.80 , 1.70) 1.15 (0.79, 1.68)
  Shared 169 57 (34) --- ---
  Doctor
YDR, YourDiseaseRisk personalized risk assessment tool with feedback; BMC, Boston Medical Center; SBCHC, South Boston Community Health




Adjusted for study group, race and decision-making preference.
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Table 5









  Decision aid only 269 116 (43) 1.42 (1.01, 2.01) 1.30 (0.90, 1.87)
  Decision aid + YDR 280 104 (37) 1.11 (0.78, 1.57) 1.03 (0.72, 1.48)
  Control 276 96 (35) --- ---
Discussed screening at study visit
  Yes 740 302 (41) 3.71 (2.02, 6.83) 3.24 (1.73, 6.05)
  No 83 13 (16) ---
Knowledge Post, quartile
  1 234 83 (35) ---
  2 120 51 (42) 1.34 (0.86 , 2.11)
  3 189 72 (38) 1.12 (0.75, 1.67)
  4 282 110 (39) 1.16 (0.81, 1.67)
Satisfaction with decision-making process, quartile
  1 218 79 (36) ---
  2 186 77 (41) 1.24 (0.83 , 1.86)
  3 237 95 (40) 1.18 (0.81, 1.72)
  4 153 60 (39) 1.14 (0.74, 1.74)
Intention (How sure are you that you will complete a CRC screening
test?)
  Completely Sure 447 194 (43) 1.63 (1.22 , 2.17) 1.69 (1.25, 2.28)
  Less Sure 362 116 (32) --- ---
Patient Preference a
  Colonoscopy 324 145 (45) ---
  FOBT 134 49 (37) 0.71 (0.47, 1.08)
  Other screening test(s) b 68 23 (34) 0.63 (0.36, 1.09)
Concordancea
  Patient/Provider Preference Same 329 164 (50) ---
  Patient/Provider Preference 100 53 (53) 1.13 (0.72 , 1.78)
Different
a
Intervention patients only (Decision aid only and Decision aid +YDR)
b




Adjusted for study group, whether screening discussed at study visit, intentions, race and decision-making preference
YDR, YourDiseaseRisk personalized risk assessment tool with feedback; BMC, Boston Medical Center; FOBT, fecal occult blood testing
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